Clinical trials: Relapsed
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02509546
- Testing
- 8-Chloroadenosine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Leukemia
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00871689
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Smoking Cessation
Effectiveness of WhatsApp Online Group Discussion for Smoking Relapse Prevention
This study aims to examine the effectiveness and cost-effectiveness of WhatsApp group discussion for smoking relapse prevention.
- Trial name
- NCT03760224
- Testing
- WhatsApp group, SMS group
- Where
- Hong Kong
- Volunteers
- 928 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Multiple Myeloma
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells…
- Trial name
- NCT00124579
- Testing
- bortezomib, dexamethasone, thalidomide
- Where
- 127 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with relapsed diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), or mantle cell lymphoma (MCL).
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Trial name
- NCT01397591
- Testing
- Ofatumumab, Bortezomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Cocaine Addiction
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
For this project, the investigators are interested in exploring a new way to extend and maintain drug abstinence in people who are addicted to crack cocaine.
- Trial name
- NCT01067846
- Testing
- Seromycin (D-cycloserine, DCS), Computerized Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Arkansas
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma
- Trial name
- NCT00068718
- Testing
- Therapeutic Allogeneic Lymphocytes
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Leukemia
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00096135
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 153 sites in United States, Australia and 3 more
- Volunteers
- 168 people
- Sponsor
- Children's Oncology Group
Relapsed or Refractory Systemic Light Chain Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB…
- Trial name
- NCT01659658
- Testing
- IXAZOMIB, Dexamethasone, Melphalan
- Where
- 66 sites in United States, Australia and 13 more
- Volunteers
- 177 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three…
- Trial name
- MoveS-it (NCT04602390)
- Testing
- ANK-700
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Anokion SA
NSCLC, Metastatic Colorectal Carcinoma
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts.
- Conditions
- NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
- Trial name
- NCT05061017
- Testing
- Pixatimod, Nivolumab, Cyclophosphamide (low dose)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Diwakar Davar
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT01611090
- Testing
- Ibrutinib, Bendamustine hydrochloride, Rituximab
- Where
- 155 sites in United States, Argentina and 19 more
- Volunteers
- 578 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT03201250
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Multiple Sclerosis
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with…
- Trial name
- NCT03606460
- Testing
- Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3
- Where
- 5 sites in United States
- Volunteers
- 141 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma.
- Trial name
- NCT00151281
- Testing
- PEPC, Thalidomide, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Squamous Cell Carcinoma of the Head and Neck
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.
- Trial name
- NCT03341936
- Testing
- Nivolumab, Lirilumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.